Novel Agonists Boost Heart Metabolism to Treat Heart Failure

Heart failure (HF) is a debilitating condition where the heart cannot pump enough blood to meet the body's demands. A key factor in its progression is impaired cardiac energy metabolism, particularly the heart's ability to efficiently use fatty acids for fuel. Current therapies often don't fully address these metabolic deficits, leaving a critical need for new approaches that can restore myocardial energy balance and function. This study specifically addresses how targeting Estrogen-related receptors (ERRs), which are nuclear receptors critical for regulating metabolic pathways, can improve cardiac metabolism and function in heart failure.

The novel Pan-ERR agonists significantly improved cardiac function in heart failure models. Treated animals showed a 25% increase in left ventricular ejection fraction (a measure of pumping efficiency) compared to controls (p<0.001). > The most significant finding was a 3.5-fold increase in cardiac fatty acid oxidation and a 40% improvement in mitochondrial respiratory capacity, indicating a robust restoration of the heart's energy metabolism. Furthermore, the agonists led to a 30% reduction in cardiac hypertrophy (enlargement of heart muscle) and fibrosis, key markers of heart failure progression. Gene expression analysis confirmed a 2-fold upregulation of genes involved in fatty acid metabolism and mitochondrial biogenesis, demonstrating the direct metabolic impact of ERR activation.